Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|November 1, 2022

Supplements and Featured Publications

  • Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
  • Volume 28
  • Issue 12

What are the current challenges to wider biosimilar use in the United States?

Plain Language Summary

Plain Language Summary

Click the image to open in a new window.

Articles in this issue

over 3 years ago

Participating Faculty: Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

over 3 years ago

Introduction to Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

over 3 years ago

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

over 3 years ago

Biosimilar medicines: what are they and how are they used?

over 3 years ago

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

over 3 years ago

What do patients and health care providers still need to know about biosimilar medicines?

over 3 years ago

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

over 3 years ago

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective